Immunosuppressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A
Open Access
- 1 December 1997
- journal article
- review article
- Published by BMJ in British Journal of Ophthalmology
- Vol. 81 (12), 1107-1112
- https://doi.org/10.1136/bjo.81.12.1107
Abstract
Fifty per cent of cases of uveitis are classified as idiopathic12 while many of the others are associated with or form part of other disease entities. However, before considering and commencing immunosuppressive therapy for uveitis, direct infectious causes must be excluded so that appropriate therapy can be commenced. Therefore, management of endogenous posterior uveitis depends on both clinical and associated laboratory based investigations to exclude any infectious aetiology. Many cases of infectious uveitis are clinically obvious—for example, opportunistic infections in immunocompromised individuals (especially in association with HIV) are increasingly frequent causes of uveitis, the treatment of which is highly dependent on specific antimicrobial therapy. In non-immunocompromised individuals, toxoplasmosis (depending on which country and region) is one of the leading causes of uveitis,28 and although immunosuppression is used to treat this condition it must be used in conjunction with appropriate antibiotic therapy to reduce the incidence of disease relapse. In certain cases, however, differentiation between infectious and non-infectious endogenous posterior uveitis (EPU) may be more difficult. For example, Lyme disease, miliary tuberculosis, or progressive outer retinal necrosis (PORN), may present with signs identical to those of EPU and, despite adequate clinical assessment, immunosuppressive therapy may have already been started on the basis that the condition was considered non-infectious. In these cases, as well as possible ‘masquerade’ conditions such as ocular lymphoma a failure to respond should be a warning sign that the diagnosis may be incorrect and needs to be reviewed. Patients with true EPU are assumed to be autoimmune in nature,19 and the aim of this review is to focus on the treatment of these primary immune mediated conditions.Keywords
This publication has 47 references indexed in Scilit:
- Short term immunosuppressive therapy and long-term immunoregulation: promises and problems.British Journal of Ophthalmology, 1996
- Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor αArthritis & Rheumatism, 1993
- Combined Cyclosporin A-Steroid-MTX Treatment in Endogenous Non-Infectious UveitisJournal of Autoimmunity, 1993
- FK506 and cyclosporin, molecular probes for studying intracellular signal transductionImmunology Today, 1993
- The use of monoclonal antibodies to achieve immunological toleranceImmunology Today, 1993
- Visual prognosis in Behçet's diseaseOcular Immunology and Inflammation, 1993
- Circulating ICAM-1 levels in serum of uveitis patientsCurrent Eye Research, 1992
- Endogenous posterior uveitis.British Journal of Ophthalmology, 1990
- A Controlled Trial of Azathioprine in Behçet's SyndromeNew England Journal of Medicine, 1990
- Bromocriptine and low dose cyclosporine in the treatment of experimental autoimmune uveitis in the rat.Journal of Clinical Investigation, 1987